JDRF T1D Fund

living with T1D globally1 of people with T1D meet target A1c2 annual global ecnomomic impact3 people living with T1D in the U S 4 immunology market by 2022 including T1D 5 A skilled team of investment professionals and volunteers with diverse knowledge in science, healthcare and technology

A holistic approach with the added benefits of the knowledge and resources of our parent company, JDRF

Sean Doherty Speaks at TEDx Boston On Reimagining Philanthropy to Drive Cures

Inversago Pharma Raises $95 million CAD in Series C Financing

Sean Doherty Appears on IVY Podcast to Discuss the Power of Venture Philanthropy

Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical

Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia

By using a venture philanthropy model, the T1D Fund is uniquely positioned to create an investment market in T1D

[The Fund] is different because it's looking for viability and commercial uptake whereas a basic research grant is just about the learning To advance the mission of JDRF we need both